Core Viewpoint - The stock of Basestone Pharmaceuticals (02616) has seen an increase of over 4%, currently trading at 5.82 HKD, with a transaction volume of 24.98 million HKD, following the announcement of its drug being included in the national medical insurance list in China [1] Group 1 - Basestone Pharmaceuticals announced that its drug, Pulatinib (100 mg capsules), has been included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List published by the National Healthcare Security Administration of China, which will take effect on January 1, 2026 [1] - Following this announcement, the stock price of Basestone Pharmaceuticals rose by 3.93% [1] Group 2 - On December 4, the non-executive director Hu Zhengguo increased his holdings in Basestone Pharmaceuticals by purchasing 1 million shares at a price of 5.7546 HKD per share, totaling 5.7546 million HKD [1] - After this purchase, Hu Zhengguo's total shareholding in the company increased to 3.471 million shares, representing a holding percentage of 0.24% [1]
港股异动 | 基石药业-B(02616)现涨超4% 普吉华获纳入国家医保目录 非执行董事近日增...